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To investigate the metastatic pathways from the primary organs to the ovaries, we examined the microscopic ﬁndings from 18
original and 18 metastatic ovarian tumors carefully. In addition, we examined the immunohistochemical ﬁndings (Victoria blue
stain for vascular invasion and D2-40 expression for lymphangio invasion) of metastatic ovarian tumors carefully. There were 4
(57%) ovarian lymphangio invasion cases in the 7 gastric cancers, but there were no cases in the 6 colorectal cancers (P < 0.05).
Therewere4(67%)ovarianvascularinvasioncasesandone(17%)livermetastasiscaseinthe6colorectalcancers,whiletherewere
noovarianvascularinvasions(P <0.05)ornolivermetastasesinthe7gastriccancers.Thepatientswithmetastaticovariantumors
originating from distant organs who were treated at the same time as the original cancers had a signiﬁcantly poorer prognosis than
the patients with ovarian tumors treated later (P < 0.05). The rate of lymphatic metastasis from the stomach to the ovary was
signiﬁcantly higher than from the colon to the ovary. In addition we hypothesized that the rate of intravascular metastasis from
the colorectum to the ovary was relatively higher than from the stomach to the ovary.
1.Introduction
Tumors metastasize to the ovaries from many organs, in-
cluding the stomach, small intestine, colon, rectum, gall
bladder, appendix, pancreas, breast, uterus, fallopian tube,
and peritoneum. Tumors from the stomach, colon, and
breast are the 3 most common neoplasms that metastasize to
the ovary. Novak and Gray advanced the following criteria
for Krukenberg tumors: (1) cancer in the ovary, (2) the
presence of mucin-producing neoplastic signet-ring cells,
and (3) ovarian stromal sarcomatoid proliferation [1]. Kru-
kenberg tumors are deﬁned as gastrointestinal cancers that
metastasize to the ovary. Recently, the term Krukenberg
tumor has been used more widely and loosely to describe
any metastatic lesion to the ovary. Metastatic tumors, except
forKrukenbergtumors,showthevariouspathologicﬁndings
in the ovary [2–4]. Recently, speciﬁc immunohistochemical
methods have been tried in order to identify the primary
neoplasm site [5, 6].
Many tumors arising from primary organs spread to the
ovaries by various routes. Direct spread is one of the path-
ways for cancer invasion into adjacent organs. Spread from
more distant sites is mainly via other routes, for example,
blood vessels, lymphatics, and surface implantation from
intra-abdominal cancers. There are many diﬀerent pathways
from distant origins, and sometimes these pathways are mix-
ed. Several studies on the metastatic routes from the stomach
have been reported [7, 8]. However, there have been few
reports on the metastatic pathways from other organs to the
ovary.
In this study, we investigated the metastatic pathways
from primary organs to the ovaries by examining the micro-
scopic ﬁndings from original and metastatic ovarian tumors
carefully, by research into the intra-abdominal ﬁndings
during surgery and by checking for positive or negative
metastasis to the liver or lung clinically. In addition, we
used immunohistochemical methods to detect vascular or
lymphangio invasion to the ovary. Furthermore, we also2 Obstetrics and Gynecology International
comparedtheprognosisofmetastaticovariantumorstreated
simultaneously as the primary cancers, versus the prognosis
ofmetastaticovariantumorstreatedaftertheprimarytumor.
2. Methods
Eighteen patients with pathologically conﬁrmed metastatic
ovarian tumor, who were treated between 2000 and 2009
at the Otsu Red Cross Hospital, were reviewed. During
that period, we experienced 200 ovarian malignancies and
18 (9.0%) metastatic ovarian carcinomas. The origins of
the 18 metastatic ovarian carcinomas were 7 gastric, 6
colorectal (2 ascending, 1 transverse, 1 sigmoid, and 2
rectal), 2 appendix, 1 small intestine, 1 gall duct, and 1
uterine corpus. We pathologically investigated any lymph
node metastasis of the originating organs, lymphangio and
vascular invasion of the ovary and direct invasion into the
ovaries, in order to determine the routes of metastasis to
the ovaries. Furthermore, we also investigated peritoneal dis-
semination during the ﬁrst surgery, and lung or liver meta-
stasis by MRI and CT. Furthermore, we also investigated the
prognosis of patients with metastatic ovarian tumors and
compared ovarian tumors treated simultaneously as the ori-
ginal cancers versus ovarian tumors treated after the original
cancer.
To study the vascular or lymphangio invasion of the
ovary, we used several staining methods. We used the
Victoria blue stain for investigating vascular invasion and
immunohistochemical staining for D2-40 for lymphangio
invasion.PositiveportionsforVictoriabluestainshowelastic
ﬁbers of vessels, and positive portions for D2-40 show lym-
phatic endothelium. With respect to the Victoria blue stain,
deparaﬃnized sections were immersed into 70% alcohol
for 1min, stained with Victoria blue solution (Muto Pure
Chemical Co., Ltd, Tokyo, Japan) for 30min, and they were
then washed by water. After those procedures, the slides were
stained by a routine hematoxylin and eosin method. With
respectto theimmunohistochemical examination forD2-40,
we performed the avidin-biotin peroxidase complex method
using a Vectastain Elite ABC kit (Vector, Burlingame, CA)
according to the manufacturer’s instructions. The sections
were deparaﬃnized and boiled in a 10mM citrate buﬀer
in a microwave oven for 3min. The sections were blocked
for nonspeciﬁc binding and then incubated overnight with
a mouse anti-D2-40 mAb (antipodoplanin monoclonal IgG,
clone D2-40, Nichirei Bioscience INC, Tokyo, Japan) at 4◦C
[9]. The sections were then treated with a biotinylated horse
antimouse immunoglobulin (Ig) G, followed by treatment
with an avidin-biotin-peroxidase complex, and were ﬁnally
stained with diaminobenzidine and 0.15% hydrogen peroxi-
dase. Counterstaining was performed with Mayer’s hema-
toxylin.
Statistical analyses were performed using the chi-square
test,Fisher’s2-tailedexacttest,andStudent’st test,onlymph
invasion,vascularinvasion,livermetastasis,pathologicaldir-
ect invasion, laterality, and prognosis.
Table 1: The primary tumor sites of metastatic ovarian cancers.
Original organs No. %
Stomch 7 38.9
Colon 6 33.3
Ascending colon 2 11.1
Transverse colon 1 5.6
Sigmoid colon 1 5.6
Rectum 2 11.1
Appendix 2 11.1
Small intestine 1 5.6
Gall duct 1 5.6
Uterine corpus 1 5.6
Total 18 100
Figure 1: Immunohistochemical expression of D2-40 in metastatic
ovarian tumor originating from gastric cancer. Immunohistochem-
ical analysis revealed the tumor to be immunoreactive for D2-40.
Positive portions (brown) show lymphatic endothelium. We found
the cancer cells in the lymphatic vessels. It means positivity for lym-
phangio invasion.
3. Results
Eighteen cases of malignant tumors with metastasis to the
ovary were identiﬁed. The average age of these patients was
58 years. The primary tumor sites were 7 gastric cancers,
6 colon cancers (2 ascending colons, 1 transverse colon, 1
sigmoid colon, and 2 rectums), 2 appendix, 1 small intestine,
1 gall duct, and 1 uterine endometrial cancer (Table 1).
We found 7 metastatic ovarian tumors originating from
gastric cancers. The average age of these patients was 53
years. Five (71%) of the 7 gastric cancers had regional lymph
node metastases (Table 2). Immunohistochemically, 4 cases
(57%) had ovarian lymphangio invasion (Figure 1), and no
one (0%) had ovarian vascular invasion. Two (29%) of the
7 gas-tric cancers had peritoneal dissemination. However,
there were no cases of liver or lung metastases. With regard
to the laterality of the metastatic ovarian tumor, 4 (57%) out
of 7 were bilateral. Four (57%) of the 7 were treated at the
same time as the original cancers, and 3 (43%) were treated
later. All patients were dead within 1–7 years after treatment.
We found 6 metastatic ovarian tumors originating from
colorectal cancers. The average age of the patients was 64Obstetrics and Gynecology International 3
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Figure 2: Victoria blue stain in metastatic ovarian tumor originat-
ing from ascending colon cancer. Positive portions (blue) show ela-
stic ﬁbers of vessels. We found the cancer cells in the vessels. It
means positivity for vascular invasion.
years. Five (83%) of the 6 colorectal cancers had regional
lymph node metastases (Table 3). Immunohistochemically,
none had lymphangio invasion, but 4 (67%) had vascular in-
vasion to the ovary (Figure 2). Furthermore, we found one
patient with liver metastasis, which we did not experience in
the gastric cancer cases. There were 2 (33%) direct invasion
cases. Their origins were the sigmoid colon and rectum,
which are near the ovaries.
With regards to other 5 metastatic ovarian tumors
ori-ginating from nongenital (1 gall duct, 2 appendix, 1
small intestine) and genital organ (1 uterine corpus), the
average age of these patients was 59 years. None of these 5
cases had ovarian lymphangio invasion or vascular invasion
(Table 3). However, 4 (80%) of the 5 cases had peritoneal
dis-seminations. In 2 (40%) of these 5 cases, we found direct
pathological invasion to the ovaries. This was approximately
the same value as invasion to the colorectal cancers (33%).
Direct invasion was found in the ovarian tumors from the
small intestine and uterine corpus, which were all near the
ovaries. Since all of these organs were adjacent except for the
gall duct, all cases except for the gall duct case were treated at
the same time as the ovarian tumors.
There were 4 (57%) ovarian lymphangio invasion cases
in the 7 gastric cancers, but there was no such case (0%)
in the 6 colorectal cancers (P<0.05) (Table 3). There were
no (0%) ovarian vascular invasion cases and no cases of
liver metastasis in the 7 gastric cancers. On the other hand,
there were 4 (67%) ovarian vascular invasion cases and one
(17%) liver metastasis case in the 6 colorectal cancers. There
were signiﬁcant diﬀerences between them (P<0.05). We
hypothesized that there was a relatively higher rate of vas-
cular metastasis in the colorectal cancers than in the gas-tric
cancers.
Direct pathological invasion into the ovary was observed
at high frequency in the primary cancers with location near
the ovaries (near the ovaries versus distant from the varies;
57% versus 0%, P<0.05) (Table 3). However, in terms of the
laterality of metastasis to the ovary, there was no signiﬁcant
diﬀerence between the primary cancers with location near
the ovaries and distant primary cancers from the ovaries
(57% versus 45%).
Seventeen (94%) of the 18 patients were already dead
despite intensive treatment. Since all of the patients were
treated at advanced stage, they had poor prognoses. We stud-
ied the prognoses of those patients in whom we treated the
metastatic ovarian tumors at the same time as the treat-
ment for the original cancers versus later and in whom the
primary cancers were near the ovaries or distant from the
ovaries (Table 3). Patients with metastatic ovarian tumors
originating from distant organs who were treated at the same
time as the original cancers had a signiﬁcantly poorer pro-
gnosis than patients with ovarian tumors treated later (time
from primary treatment to death: 1.60 years versus 3.17
years, P< 0.05).
4. Discussion
Tumors can spread to the ovary by several pathways, such as
direct spread, transcoelomic dissemination, hematogeneous
spread, and lymphatic spread [10]. However, there are many
cases with mixed metastatic pathways, because the original
cancers are detected at advanced stage. It is very diﬃcult to
determine the speciﬁc pathway of tumor spread. However, it
is possible to propose trends in the pathways of each primary
cancer to the ovary using detailed clinicopathological exami-
nations.
In our study, the rate of lymphatic metastasis from the
stomach to the ovary was signiﬁcantly higher than from the
colontotheovary.Thereasonmaybeduetolymphaticvessel
anatomy.Urogenitallymphvesseltractsgiveriseviathelum-
bartrunkstothereceptaculumchili,whichjointheintestinal
trunks. The intestinal trunks connect via celiac nodes to
the gastric nodes, hepatic nodes, pancreaticolineal nodes,
and mesenteric nodes (superior mesenteric and mesocolic
nodes). Since the distance from the receptaculum chili to the
gastric nodes is shorter than to the mesenteric nodes, gastric
cancer cells metastasize easily via the receptaculum chili to
the urogenital lymph vessel trunks, which supply the ovaries.
Al-Agha and Nicastri also suggested that lymphatic spread
was the most likely route of metastasis of gastric cancer to
the ovaries [8]. Their opinion supports our hypothesis.
In our study, the rate of vascular metastasis from the
colo-rectum to the ovary was signiﬁcantly higher than
from the stomach to the ovary (using immunohistochemical
methods). In addition, one had liver metastasis in the colo-
rectal cancers. We suggest that the reason why is because
the number, area, and volume of vessels in the colon are all
larger than those of the stomach. Moore et al. reported that
the route of metastasis from the colon to the ovary was sus-
pected to be through hematogeneous pathways, because the
laterality of the metastasis to the ovary in colon cancers did
not correspond to the side of the primary lesion [11].
Those cancers arising from origin of primary tumors
with location near the ovaries were more likely to invade the
ovaries directlythan cancersarising fromdistant organs(P<
0.05). All of these organs and ovaries are intrapelvic tissues
and thus are linked together by the peritoneum. However,
the primary cancers with location near the ovaries do not
always invade the ovary on the same side. There was noObstetrics and Gynecology International 5
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signiﬁcant diﬀerence in metastatic laterality to the ovary
between primary cancers with location near the ovaries and
distant primary cancers from the ovaries in this study. When
theprimarycancerswithlocationneartheovariesarepresent
in the center of the pelvis or in appendix, then the cancers
will likely invade to both ovaries.
The absence of residual disease after treatment and
a limited disease extent are favorable prognostic factors
for metastatic ovarian tumors [12–15]. The amount of
residual tumor after primary surgery is likely a prognostic
factor [16, 17]. The prognoses of patients with metastatic
ovarian tumors are generally poor, because the primary
cancers are found at advanced stage [18, 19]. We therefore
studied the diﬀerences in prognosis between time and space.
Those patients with metastatic ovarian tumors originating
from distant organs who were treated at the same time as
the primary cancers had a signiﬁcantly poorer prognosis
than patients with ovarian tumors treated later (time from
primary treatment to death: 1.60 years versus 3.17 years,
P< 0.05). This means that the former patients had distant
metastasis at the time of the ﬁrst surgical treatment, whereas
the latter patients did not have distant metastases at the time
of their primary surgery. In brief, the patients with distant
metastases at the time of primary surgery had a poorer
prognosis than the patients without distant metastases.
5. Conclusion
The rate of lymphatic metastasis from the stomach to the
ovary was signiﬁcantly higher than from the colon to the
ovary. In addition, we hypothesized that the rate of intra-
vascular metastasis from the colo-rectum to the ovary was
relatively higher than from the stomach to the ovary.
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